BidaskClub Lowers Paratek Pharmaceuticals (PRTK) to Strong Sell

BidaskClub lowered shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a research note released on Saturday morning.

PRTK has been the topic of a number of other research reports. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price objective on the stock in a report on Saturday, August 5th. Cantor Fitzgerald reissued an overweight rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 8th. Raymond James Financial reissued a strong-buy rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Monday, September 18th. Finally, Guggenheim began coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a buy rating and a $44.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Paratek Pharmaceuticals presently has an average rating of Buy and a consensus price target of $40.00.

Shares of Paratek Pharmaceuticals (NASDAQ PRTK) opened at $18.55 on Friday. Paratek Pharmaceuticals has a 12 month low of $13.10 and a 12 month high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.

Several institutional investors and hedge funds have recently bought and sold shares of PRTK. TIAA CREF Investment Management LLC boosted its holdings in shares of Paratek Pharmaceuticals by 11.7% in the first quarter. TIAA CREF Investment Management LLC now owns 75,076 shares of the specialty pharmaceutical company’s stock worth $1,445,000 after buying an additional 7,844 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Paratek Pharmaceuticals by 9.5% during the first quarter. Vanguard Group Inc. now owns 724,300 shares of the specialty pharmaceutical company’s stock valued at $13,942,000 after purchasing an additional 63,121 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Paratek Pharmaceuticals by 10.7% during the first quarter. Geode Capital Management LLC now owns 148,962 shares of the specialty pharmaceutical company’s stock valued at $2,867,000 after purchasing an additional 14,392 shares in the last quarter. Morgan Stanley lifted its holdings in Paratek Pharmaceuticals by 160.2% during the first quarter. Morgan Stanley now owns 154,693 shares of the specialty pharmaceutical company’s stock valued at $2,978,000 after purchasing an additional 95,243 shares in the last quarter. Finally, Credit Suisse AG lifted its holdings in Paratek Pharmaceuticals by 36.6% during the first quarter. Credit Suisse AG now owns 18,110 shares of the specialty pharmaceutical company’s stock valued at $349,000 after purchasing an additional 4,853 shares in the last quarter. 84.30% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Paratek Pharmaceuticals (PRTK) to Strong Sell” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/05/bidaskclub-lowers-paratek-pharmaceuticals-prtk-to-strong-sell.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply